GlassScriptPhysician profile
Marc L Lee
NPI 1962498709
$9,262.65
in general payments reported to CMS, 2019-2025
51 companies · $470 in 2025
The $470 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,465 · 2020: $1,047 · 2021: $2,228 · 2022: $2,913 · 2023: $1,052 · 2024: $87.11 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,609.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,096.42 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $1,045.78 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $679.63 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $571.59 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $570.08 | 2019-2023 | Farxiga |
| Glaxosmithkline, LLC. | $555.43 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $312.62 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $295.59 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $256.54 | 2019-2023 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $248.98 | 2019-2023 | |
| Abbott Laboratories | $239.28 | 2021-2023 | Freestyle Libre 3, Freestyle Libre 2, Octrode |
| Eisai INC. | $228.91 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $220.03 | 2019-2023 | Dificid |
| Kowa Pharmaceuticals America, INC. | $212.90 | 2019-2023 | Seglentis, Livalo |
| Amarin Pharma, INC. | $210.31 | 2020-2022 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.